3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
23
Lung Neoplasms
11
Neoplasm Metastasis
4
Squamous Cell Carcinoma of Head and Neck
2
Solid Tumor
2
Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Noonan Syndrome
1
Non-Small Cell Lung Cancer With EGFR Mutation
1
Neoplasms, Squamous Cell
1
Neoplasms by Site
1
Mesothelioma
1
Lung Diseases
1
Inhibition, Psychological
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Interventions
Etoposide
18
Carboplatin
18
pembrolizumab
15
Nivolumab
11
Cisplatin
11
atezolizumab
8
Topotecan
8
Irinotecan
7
Temozolomide
6
Paclitaxel
5
PM 01183
5
Ipilimumab
5
Gemcitabine
5
olaparib
4
Radiotherapy
4
Docetaxel
4
surufatinib
3
durvalumab
3
carfilzomib
3
Bevacizumab
3
veliparib
2
trilaciclib
2
sacituzumab govitecan
2
rovalpituzumab tesirine
2
obatoclax
2
niraparib
2
navitoclax
2
lorvotuzumab mertansine
2
lenvatinib
2
fluzoparib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Small Cell Lung Carcinoma
×
osimertinib
×
Clear all
NCT07153055
2025-12-18
LOTS
Indiana University
Phase 1/2
Not yet recruiting
16 enrolled